ArticleNanomaterials (Basel, Switzerland)2026
Banana Passion Fruit-Mediated Green Synthesis of Copper(I) Iodide Nanoparticles for Concrete Biodeterioration Control: Antimicrobial Activity, Cytotoxicity, and Mechanical Compatibility.
Article in Nanomaterials (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to synthesize copper(I) iodide nanoparticles (CuI NPs) through a green route using taxo (banana passion fruit) extract as a natural capping and stabilizing agent, and to evaluate their antimicrobial performance against microorganisms isolated from concrete, together with a preliminary cytotoxicity screening. The obtained nanoparticles were characterized by ultraviolet-visible spectroscopy (UV-Vis), Fourier-transform infrared spectroscopy (FTIR), transmission electron microscopy (TEM), scanning electron microscopy coupled with energy-dispersive X-ray spectroscopy (SEM-EDS), dynamic light scattering (DLS), and X-ray diffraction (XRD). UV-Vis spectra recorded in the 200-704 nm range showed a strong absorption band at 224 nm, consistent with electronic transitions associated with nanostructured CuI. FTIR analysis revealed extract-derived biomolecules adsorbed on the nanoparticle surface, with bands assigned to aliphatic C-H, aromatic moieties, and C-O/C-O-C vibrations, supporting the formation of an organic capping layer. DLS analysis showed a mean hydrodynamic diameter of approximately 32 nm in aqueous suspension, whereas TEM revealed particle sizes ranging from 13 to 42 nm. XRD confirmed a predominantly cubic CuI phase, while SEM-EDS identified Cu and I as the main elements, with minor signals attributed to residual organic coating and/or trace species from the synthesis medium. The CuI NPs exhibited antimicrobial activity against microorganisms isolated from medium-strength concrete, producing inhibitory effects at all tested concentrations (0.014, 0.0087, and 0.0035 mol/L). Preliminary cytotoxicity screening using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay in human foreskin fibroblast (HFF), human breast adenocarcinoma (MCF7), and human glioblastoma (U251) cell lines showed dose- and time-dependent reductions in metabolic viability. The 1.0 mol/L formulations, particularly the precipitated fraction, produced stronger cytotoxic effects, whereas the 0.1 mol/L formulations, especially the residual fraction, preserved comparatively higher metabolic viability. Overall, these findings suggest that taxo-mediated CuI NPs are promising antimicrobial candidates for concrete biodeterioration control, while further colloidal and biological studies are required to better define their behavior under cell-culture conditions and optimize their safe application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.